Onconetix, Inc.

NasdaqCM:ONCO Stock Report

Market Cap: US$512.8k

Onconetix Balance Sheet Health

Financial Health criteria checks 3/6

Onconetix has a total shareholder equity of $15.8M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $24.9M and $9.2M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$5.22m
EquityUS$15.76m
Total liabilitiesUS$9.16m
Total assetsUS$24.93m

Recent financial health updates

Recent updates

Here's Why We're Not Too Worried About Blue Water Vaccines' (NASDAQ:BWV) Cash Burn Situation

Jan 24
Here's Why We're Not Too Worried About Blue Water Vaccines' (NASDAQ:BWV) Cash Burn Situation

Blue Water plans to evaluate BWV-201 vaccine for pneumococcal pneumonia

Oct 11

Blue Water Vaccines stock jumps ~22% premarket on plans to develop monkeypox shot

Aug 17

Blue Water Vaccines in pact to study Alzheimer’s vaccine

Jul 20

Blue Water Vaccines: Estimates And Expectations

May 17

Financial Position Analysis

Short Term Liabilities: ONCO's short term assets ($6.1M) do not cover its short term liabilities ($9.1M).

Long Term Liabilities: ONCO's short term assets ($6.1M) exceed its long term liabilities ($26.1K).


Debt to Equity History and Analysis

Debt Level: ONCO is debt free.

Reducing Debt: ONCO had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ONCO has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: ONCO has less than a year of cash runway if free cash flow continues to reduce at historical rates of 25.5% each year


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/20 14:52
End of Day Share Price 2026/04/20 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Onconetix, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Vernon BernardinoH.C. Wainwright & Co.
Jason McCarthyMaxim Group